Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics


Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $515.56 USD

28.54 (-5.25%)

Updated Jan 27 4:00pm

Add REGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • REGN has a higher market value than 96.01% of US stocks; more precisely, its current market capitalization is $58,058,878,242.
  • With a year-over-year growth in debt of 278.11%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 94.37% of about US stocks.
  • In terms of volatility of its share price, REGN is more volatile than merely 12.89% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Regeneron Pharmaceuticals Inc are VRTX, SNPS, EA, ADI, and CDNS.
  • REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to www.regeneron.com.

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $515.56 52-week high $664.64
Prev. close $544.10 52-week low $328.13
Day low $512.94 Volume 1,432,882
Day high $541.97 Avg. volume 1,013,523
50-day MA $506.71 Dividend yield N/A
200-day MA $569.03 Market Cap 55.01B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio


Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$515.56$608.09 12%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 54th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 12.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is 72.22 -- which is good for besting 94.36% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 15.58% of the free cash flow producing stocks we're observing.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.27% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%10%
1%11%
2%12%
3%13%
4%14%
5%15%

FONR, CMD, DXCM, UNH, and FZMD can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Regeneron COVID-19 antibody drug effective in preventing COVID-19

Regeneron (REGN) reports that data from a late-stage trial evaluating its casirivimab and imdevimab antibody cocktail known as REGEN-COV indicates it is effective in preventing COVID-19 infection.Interim analysis on the first 400 patients randomized to receive the cocktail or a placebo showed those in the active arm had 100% prevention...

Seeking Alpha | January 26, 2021

Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation

After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST ). The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630. Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50. The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinom...

Benzinga | January 25, 2021

Thinking about trading options or stock in Niu Technologies, Regeneron Pharmaceuticals, General Electric, Merck, or Axon Enterprise?

NEW YORK, Jan. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIU, REGN, GE, MRK, and AAXN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…

PR Newswire | January 25, 2021

Regeneron Upgraded as BMO Sees Potential for Eye, Skin Drugs

Regeneron 'is well positioned heading into 2021 and see current levels as an attractive entry point,' BMO wrote, upgrading the stock.

Yahoo | January 25, 2021

Dow Jones Today Lags, Nasdaq Rallies As Merck Exits Covid Vaccine Race; Apple, Microsoft, AMD Rise Ahead Of Earnings

SciPlay and JD.com were early leaders, and Apple led the Dow Jones today as stocks geared for the heaviest week of the Q4 reporting season.

Yahoo | January 25, 2021

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 6.75%
3-mo -7.24%
6-mo -18.43%
1-year 49.84%
3-year 37.72%
5-year 22.73%
YTD 6.72%
2020 28.66%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1059 seconds.